SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar

Cassava Sciences (NASDAQ:SAVA) stock is on the rise Wednesday after revealing interim results from a recent clinical trial.

A close-up shot of a hand holding a variety of pills

Source: Shutterstock

Here’s everything potential investors need to know about SAVA stock and the interim study results today.

  • Those trial results saw improvements in the cognitive abilities of patients suffering from Alzheimer’s disease that were taking SAVA’s simufilam.
  • The company says that these positive results support moving forward with a Phase 3 study of the treatment.
  • Cassava Sciences notes that it plans to start a Phase 3 clinical trial in the second half of 2021.
  • It’s also planning to increase enrollment in the open-label study to 150 patients from the previous 100 patients.
  • The company is also seeking advice from experts on other enhancements for the open-label study.
  • Cassava Sciences clinical-stage biopharmaceutical company focused on neuroscience.
  • This has it targeting the development of treatments for people suffering from debilitating neurodegenerative conditions.
  • The company’s lead drug candidate is simufilam, which restores the normal shape and function of altered filamin A in the brain.
  • To go along with its Alzheimer’s disease treatment, it’s also working on a way to test for the illness.
  • It calls this SavaDx and it’s a diagnostic tool that can detect Alzheimer’s with just a blood test.
  • The company notes that its research is supported by the National Institutes of Health, which provides it with scientific and financial backing.
  • The company was founded in 1998 and has a market capitalization of about $910 million.

SAVA stock was up 15.8% as of Wednesday morning.

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.


Article printed from InvestorPlace Media, https://investorplace.com/2021/02/sava-stock-12-things-for-investors-to-know-about-cassava-sciences-as-shares-soar/.

©2021 InvestorPlace Media, LLC